title: Imatinib: novel treatment of immune-mediated kidney injury.
abstract: The treatments for many autoimmune diseases are limited in efficacy, and long-term use is associated with severe adverse events. The tyrosine kinase inhibitors have proven to be well tolerated for long treatment periods, with minimal adverse events, in the oncology population. These agents have recently been used to treat autoimmune diseases. We review the potential mechanisms whereby tyrosine kinase inhibitors may modulate the immune response and inhibit fibrogenesis and discuss the current evidence for their use in the treatment of autoimmune diseases of the kidney.
authors: Division of Nephrology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. ericlwallace@uab.edu
authors: Eric
authors: E
authors: Wallace
authors: Leslie
authors: L
authors: Gewin
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology; D005355:Fibrosis / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D007155:Immunologic Factors / Q000494:pharmacology; D007674:Kidney Diseases / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000502:physiology
chemical_list: D001549:Benzamides; D007155:Immunologic Factors; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016212:Transforming Growth Factor beta; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases